| CPC A61K 31/5513 (2013.01) [A61K 31/13 (2013.01); A61K 31/27 (2013.01); A61K 31/445 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01)] | 9 Claims |
|
1. A method of treating a neurological disease, wherein said neurological disease is selected from the groups consisting of Alzheimer's disease and a subtype thereof, in a subject in need thereof, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula II:
 wherein:
RII′ is −H;
BII is cyclopentyl optionally substituted with one or more RBII,
XII′ is —NR*—, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, or imidazolidinyl, each optionally and independently substituted with one or more RXII′;
XII is an C1-C10 alkylenyl wherein optionally one or more carbon atoms are each independently replaced by O, —C(O)—, —NR*—, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl or imidazolidinyl, and wherein the alkylenyl or said piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl or imidazolidinyl is optionally and independently substituted with one or more RXII;
YII is pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiophenyl, furanyl, pyrrolyl, imidazolyl, thiazolyl, pyrazolyl, triazolyl, oxazolyl, benzoxazolyl, or benzoisoxazolyl, each optionally and independently substituted with one or more RYII,
each R* is independently-H or optionally substituted C1-C6 alkyl;
each RBII is independently C1-C6 alkyl, C1-C6 haloalkyl, halo, or —CN;
each RXII′ is independently C1-C6 alkyl, C1-C6 haloalkyl, halo or —CN;
each RXII is independently C1-C6 alkyl, C1-C6 haloalkyl, halo, —CN, cycloalkyl, or —NR*2; and
each RYII is independently C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), halo, or —CN.
|